Vascular adhesion protein-1 (VAP-1)

  • Marko Salmi
  • Sirpa Jalkanen
Part of the Progress in Inflammation Research book series (PIR)


In 1980s the leukocyte adhesion molecules and their ligands on the vascular endothelium were thought to explain tissue-selective, or even tissue-specific, leukocyte traffic. At the same time it became apparent that vessels in inflamed joints displayed binding characteristics clearly distinct from those in peripheral lymph nodes, gut and skin. In search of joint-selective endothelial adhesion molecules we therefore isolated vascular fragments from inflamed human synovial samples to raise monoclonal antibodies (mAbs) against endothelial antigens [1]. From this screen, we identified an mAb, 1B2, that readily stained synovial blood vessels and inhibited lymphocyte adhesion in classical frozen section binding assays. Differential screening against other known endothelial adhesion molecules allowed us to conclude that we had identified a new adhesion molecule. This antigen was named vascular adhesion protein-1 (VAP-1; nowadays also known by the gene name amine oxidase copper containing -3, AOC3).


Amine Oxidase Diamine Oxidase Semicarbazide Sensitive Amine Oxidase Amine Oxidase Copper Leukocyte Binding 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Salmi M, Jalkanen S (1992) A 90-kilodalton endothelial cell molecule mediating lymphocyte binding in humans. Science 257: 1407–1409PubMedCrossRefGoogle Scholar
  2. 2.
    Salmi M, Kalimo K, Jalkanen S (1993) Induction and function of vascular adhesion protein-1 at sites of inflammation. J Exp Med 178: 2255–2260PubMedCrossRefGoogle Scholar
  3. 3.
    Smith DJ, Salmi M, Bono P, Hellman J, Leu T, Jalkanen S (1998) Cloning of vascular adhesion protein-1 reveals a novel multifunctional adhesion molecule. J Exp Med 188: 17–27PubMedCrossRefGoogle Scholar
  4. 4.
    Jalkanen S, Salmi M (2001) Cell surface monoamine oxidases: enzymes in search of a function. EMBO J 20: 3893–3901PubMedCrossRefGoogle Scholar
  5. 5.
    Klinman JP, Mu D (1994) Quinoenzymes in biology. Annu Rev Biochem 63: 299–344PubMedCrossRefGoogle Scholar
  6. 6.
    Arvilommi A-M, Salmi M, Kalimo K, Jalkanen S (1996) Lymphocyte binding to vascular endothelium in inflamed skin revisited: a central role for vascular adhesion protein-1 (VAP-1). Eur J Immunol 26: 825–833PubMedCrossRefGoogle Scholar
  7. 7.
    Salmi M, Rajala P, Jalkanen S (1997) Homing of mucosal leukocytes to joints. Distinct endothelial ligands in synovium mediate leukocyte-subtype specific adhesion. J Clin Invest 99: 2165–2172PubMedCrossRefGoogle Scholar
  8. 8.
    McNab G, Reeves JL, Salmi M, Hubscher S, Jalkanen S, Adams DH (1996) Vascular adhesion protein 1 mediates binding of T cells to human hepatic endothelium. Gastro-enterology 110:522–528CrossRefGoogle Scholar
  9. 9.
    Jaakkola K, Jalkanen S, Kaunismäki K, Vänttinen E, Saukko P, Alanen K, Kallajoki M, Voipio-Pulkki L-M, Salmi M (2000) Vascular adhesion protein-1, intercellular adhesion molecule-1 and P-selectin mediate leukocyte binding to ischemic heart in humans. J Am Coll Cardiol 36: 122–129PubMedCrossRefGoogle Scholar
  10. 10.
    Salmi M, Yegutkin G, Lehvonen R, Koskinen K, Salminen T, Jalkanen S (2001) A cell surface amine oxidase directly controls lymphocyte migration. Immunity 14: 265–276PubMedCrossRefGoogle Scholar
  11. 11.
    Koskinen K, Vaimo PJ, Smith DJ, Pihlavisto M, Yla-Herttuala S, Jalkanen S, Salmi M (2004) Granulocyte transmigration through endothelium is regulated by the oxidase activity of vascular adhesion protein-1 (VAP-1). Blood 103: 3388–3395PubMedCrossRefGoogle Scholar
  12. 12.
    Lalor PF, Edwards S, McNab G, Salmi M, Jalkanen S, Adams DH (2002) Vascular adhesion protein-1 mediates adhesion and transmigration of lymphocytes on human hepatic endothelial cells. J Immunol 169: 983–992PubMedGoogle Scholar
  13. 13.
    Tohka S, Laukkanen M-L, Jalkanen S, Salmi M (2001) Vascular adhesion protein 1 ions as a molecular brake during granulocyte rolling and mediates their recruitment in vivo. FASEB J 15: 373–382PubMedCrossRefGoogle Scholar
  14. 14.
    Merinen M, Irjala H, Salmi M, Jaakkola I, Hanninen A, Jalkanen S (2005) Vascular adhesion protein-1 is involved in both acute and chronic inflammation in the mouse. Am J Pathol 166: 793–800PubMedGoogle Scholar
  15. 15.
    Martelius T, Salaspuro V, Salmi M, Krogerus L, Hockerstedt K, Jalkanen S, Lautenschlager I (2004) Blockade of vascular adhesion protein-1 inhibits lymphocyte at liver allograft rejection. Am J Pathol 165: 1993–2001PubMedGoogle Scholar
  16. 16.
    Bonder C, Swain MG, Zbytnuik LD, Norman MU, Yamanouchi J, Santamaria P, Ajuebor M, Salmi M, Jalkanen S, Kubes P (2005) Rules of recruitment of trafficking Th1 and Th2 cells in inflamed liver. Immunity 23: 153–163PubMedCrossRefGoogle Scholar
  17. 17.
    Stolen CM, Marttila-Ichihara F, Koskinen K, Yegutkin GG, Turja R, Bono P, Skurnik M, Hanninen A, Jalkanen S, Salmi M (2005) Absence of the endothelial oxidase AOC3 leads to abnormal leukocyte traffic in vivo. Immunity 22: 105–115PubMedCrossRefGoogle Scholar
  18. 18.
    Salter-Cid LM, Wang E, O’Rourke AM, Miller A, Gao H, Huang L, Garcia A, Linnik MD (2005) Anti-inflammatory effects of inhibiting the amine oxidase activity of SSAO. J Pharmacol Exp Ther 315:553–562.PubMedCrossRefGoogle Scholar
  19. 19.
    Xu HL, Salter-Cid L, Linnik M, Wang E, Paisansathan C, Pelligrino D (2005) Vascular adhesion protein-1 plays an important role in post-ischemic inflammation and neuropathology in diabetic, estrogen-treated ovariectomized female rats subjected to transient forebrain ischemia. J Pharmacol Exp Ther 317:19–29PubMedCrossRefGoogle Scholar
  20. 20.
    Marttila-Ichihara F, Smith DJ, Stolen C, Yegutkin GG, Elima K, Mercier N, Kiviranta R, Pihlavisto M, Alaranta S, Pentikainen U et al (2006) Vascular amine oxidases are needed for leukocyte extravasation into inflamed joints in vivo. Arthritis Rheum 54: 2852–2862PubMedCrossRefGoogle Scholar
  21. 21.
    Salmi M, Jalkanen S (2005) Cell-surface enzymes in control of leukocyte trafficking. Nat Rev Immunol 5: 760–771PubMedCrossRefGoogle Scholar
  22. 22.
    Haddock RC, Mack P, Leal S, Baenziger NL (1990) The histamine degradative uptake pathway in human vascular endothelial cells and skin fibroblasts is dependent on extracellular Na+ and Cl-. J Biol Chem 265: 14395–14401PubMedGoogle Scholar
  23. 23.
    Li W, Liu G, Chou IN, Kagan HM (2000) Hydrogen peroxide-mediated, lysyl oxidase — dependent chemotaxis of vascular smooth muscle cells. J Cell Biochem 78: 550–557PubMedCrossRefGoogle Scholar
  24. 24.
    Erler JT, Bennewith KL, Nicolau M, Dornhofer N, Kong C, Le QT, Chi JT, Jeffrey SS, Giaccia AJ (2006) Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440: 1222–1226PubMedCrossRefGoogle Scholar
  25. 25.
    Bono P, Jalkanen S, Salmi M (1999) Mouse vascular adhesion protein-1 (VAP-1) is a sialoglycoprotein with enzymatic activity and is induced in diabetic insulitis. Am J Pathol 155: 1613–1624PubMedGoogle Scholar
  26. 26.
    Jaakkola K, Nikula T, Holopainen R, Vähäsilta T, Matikainen M-T, Laukkanen M-L, Huupponen R, Haikola L, Nieminen L, Hiltunen J et al (2000) In vivo detection of vascular adhesion protein-1 in experimental inflammation. Am J Pathol 157: 463–471PubMedGoogle Scholar
  27. 27.
    Vainio PJ, Kortekangas-Savolainen O, Mikkola JH, Jaakkola K, Kalimo K, Jalkanen S, Veromaa T (2005) Safety of blocking vascular adhesion protein-1 in patients with contact dermatitis. Basic Clin Pharmacol Toxicol 96: 429–435PubMedCrossRefGoogle Scholar
  28. 28.
    Arvilommi A-M, Salmi M, Jalkanen S (1997) Organ-selective regulation of vascular adhesion protein-1 expression in man. Eur J Immunol 27: 1794–1800PubMedCrossRefGoogle Scholar
  29. 29.
    Salmi M, Jalkanen S (2006) Developmental regulation of the adhesive and enzymatic activity of vascular adhesion protein-1 (VAP-1) in humans. Blood 108: 1555–1561PubMedCrossRefGoogle Scholar
  30. 30.
    Boomsma F, van den Meiracker AH, Winkel S, Aanstoot HJ, Batstra MR, Man in,t Veld AJ, Bruining GJ (1999) Circulating semicarbazide-sensitive amine oxidase is raised both in type I (insulin-dependent), in type II (non-insulin-dependent) diabetes mellitus and even in childhood type I diabetes at first clinical diagnosis. Diabetologia 42: 233–237PubMedCrossRefGoogle Scholar
  31. 31.
    Karadi I, Meszaros Z, Csanyi A, Szombathy T, Hosszufalusi N, Romics L, Magyar K (2002) Serum semicarbazide-sensitive amine oxidase (SSAO) activity is an independent marker of carotid atherosclerosis. Clin Chim Acta 323: 139–146PubMedCrossRefGoogle Scholar
  32. 32.
    Boomsma F, van Veldhuisen DJ, de Kam PJ, Man in,t Veld AJ, Mosterd A, Lie KI, Schalekamp MA (1997) Plasma semicarbazide-sensitive amine oxidase is elevated in patients with congestive heart failure. Cardiovasc Res 33: 387–391PubMedCrossRefGoogle Scholar
  33. 33.
    Meszaros Z, Szombathy T, Raimondi L, Karadi I, Romics L, Magyar K (1999) Elevated serum semicarbazide-sensitive amine oxidase activity in non-insulin dependent diabetes mellitus: correlation with body mass index and serum triglyceride. Metabolism 48: 113–117PubMedCrossRefGoogle Scholar
  34. 34.
    Kurkijärvi R, Yegutkin GG, Gunson BK, Jalkanen S, Salmi M, Adams DH (2000) Circulating soluble vascular adhesion protein 1 accounts for the increased serum monoamine oxidase activity in chronic liver disease. Gastroenterology 119: 1096–1103PubMedCrossRefGoogle Scholar
  35. 35.
    Gronvall-Nordquist JL, Backlund LB, Garpenstrand H, Ekblom J, Landin B, Yu PH, Oreland L, Rosenqvist U (2001) Follow-up of plasma semicarbazide-sensitive amine oxidase activity and retinopathy in Type 2 diabetes mellitus. J Diabetes Complications 15:250–256PubMedCrossRefGoogle Scholar
  36. 36.
    Boomsma F, Derkx FH, van den Meiracker AH, Man in,t Veld AJ, Schalekamp MA (1995) Plasma semicarbazide-sensitive amine oxidase activity is elevated in diabetes mellitus and correlates with glycosylated haemoglobin. Clin Sci (Lond) 88: 675–679Google Scholar
  37. 37.
    Kurkijärvi R, Adams DH, Leino R, Möttönen T, Jalkanen S, Salmi M (1998) Circulating form of human vascular adhesion protein-1 (VAP-1): increased serum levels in inflammatory liver diseases. J Immunol 161: 1549–1557PubMedGoogle Scholar
  38. 38.
    Salmi M, Stolen C, Jousilahti P, Yegutkin GG, Tapanainen P, Janatuinen T, Knip M, Jalkanen S, Salomaa V (2002) Insulin-regulated increase of soluble vascular adhesion protein-1 in diabetes. Am J Pathol 161: 2255–2262PubMedGoogle Scholar
  39. 39.
    Gokturk C, Nilsson J, Nordquist J, Kristensson M, Svensson K, Soderberg C, Israelson M, Garpenstrand H, Sjoquist M, Oreland L et al (2003) Overexpression of semicarbazide-sensitive amine oxidase in smooth muscle cells leads to an abnormal structure of the aortic elastic laminas. Am J Pathol 163: 1921–1928PubMedGoogle Scholar
  40. 40.
    Stolen CM, Madanat R, Marti L, Kari S, Yegutkin GG, Sariola H, Zorzano A, Jalkanen S (2004) Semicarbazide-sensitive amine oxidase overexpression has dual consequences: insulin mimicry and diabetes-like complications. FASEB J 18:702–704PubMedGoogle Scholar
  41. 41.
    Abella A, Garcia-Vicente S, Viguerie N, Ros-Baro A, Camps M, Palacin M, Zorzano A, Marti L (2004) Adipocytes release a soluble form of VAP-1/SSAO by a metalloprotease-dependent process and in a regulated manner. Diabetologia 47: 429–438PubMedCrossRefGoogle Scholar
  42. 42.
    Airenne TT, Nymalm Y, Kidron H, Smith DJ, Pihlavisto M, Salmi M, Jalkanen S, Johnson MS, Salminen TA (2005) Crystal structure of the human vascular adhesion protein-1: unique structural features with functional implications. Protein Sci 14: 1964–1974PubMedCrossRefGoogle Scholar
  43. 43.
    Jakobsson E, Nilsson J, Ogg D, Kleywegt GJ (2005) Structure of human semicarbazide-sensitive amine oxidase/vascular adhesion protein-1. Acta Crystallogr D Biol Crystallogr 61: 1550–1562PubMedCrossRefGoogle Scholar
  44. 44.
    Maula SM, Salminen T, Kaitaniemi S, Nymalm Y, Smith DJ, Jalkanen S (2005) Carbohydrates located on the top of the “cap” contribute to the adhesive and enzymatic functions of vascular adhesion protein-1. Eur J Immunol 35: 2718–2727PubMedCrossRefGoogle Scholar
  45. 45.
    Moldes M, Fève B, Pairault J (1999) Molecular cloning of a major mRNA species in murine 3T3 adipocyte lineage, differentiation-dependent expression, regulation, and identification as semicarbazide-sensitive amine oxidase. J Biol Chem 274: 9515–9523PubMedCrossRefGoogle Scholar
  46. 46.
    Enrique-Tarancon G, Marti L, Morin N, Lizcano JM, Unzeta M, Sevilla L, Camps M, Palacin M, Testar X, Carpéné C et al (1998) Role of semicarbazide-sensitive amine oxidase on glucose transport and GLUT4 recruitment to the cell surface in adipose cells. J Biol Chem 273: 8025–8032PubMedCrossRefGoogle Scholar
  47. 47.
    Abella A, Marti L, Camps M, Claret M, Fernandez-Alvarez J, Gomis R, Guma A, Viguerie N, Carpene C, Palacin M et al (2003) Semicarbazide-sensitive amine oxidase/ vascular adhesion protein-1 activity exerts an antidiabetic action in Goto-Kakizaki rats. Diabetes 52: 1004–1013PubMedCrossRefGoogle Scholar
  48. 48.
    Marti L, Abella A, Carpene C, Palacin M, Testar X, Zorzano A (2001) Combined treatment with benzylamine and low dosages of vanadate enhances glucose tolerance and reduces hyperglycemia in streptozotocin-induced diabetic rats. Diabetes 50: 2061–2068PubMedCrossRefGoogle Scholar
  49. 49.
    Jaakkola K, Kaunismäki K, Tohka S, Yegutkin G, Vänttinen E, Havia T, Pelliniemi LJ, Virolainen M, Jalkanen S, Salmi M (1999) Human vascular adhesion protein-1 in smooth muscle cells. Am J Pathol 155: 1953–1965PubMedGoogle Scholar
  50. 50.
    Mercier N, Osborne-Pellegrin M, El Hadri K, Kakou A, Labat C, Loufrani L, Henrion D, Challande P, Jalkanen S, Feve B et al (2006) Carotid arterial stiffness, elastic fibre network and vasoreactivity in semicarbazide-sensitive amine-oxidase null mouse. Cardiovasc Res 72: 349–357PubMedCrossRefGoogle Scholar
  51. 51.
    Kinemuchi H, Sugimoto H, Obata T, Satoh N, Ueda S (2004) Selective inhibitors of membrane-bound semicarbazide-sensitive amine oxidase (SSAO) activity in mammalian tissues. Neurotoxicology 25: 325–335PubMedCrossRefGoogle Scholar

Copyright information

© Birkhäuser Verlag Basel/Switzerland 2007

Authors and Affiliations

  • Marko Salmi
    • 1
  • Sirpa Jalkanen
    • 2
  1. 1.MediCity Research Laboratory and Department of Microbiology and ImmunologyUniversity of TurkuTurkuFinland
  2. 2.Department of Bacterial and Inflammatory DiseasesNational Public Health InstituteTurkuFinland

Personalised recommendations